India Considers Price Caps On Medical Devices
This article was originally published in PharmAsia News
The government is set to gather data on the price, supply and availability of medical devices in India and compare them with other countries in advance of considering price controls. The National Pharmaceutical Pricing Authority has been told to gather the information as part of an effort to set guidelines for negotiations with device makers for a cap on the prices of their new products, both drugs and medical devices, as part of the marketing-approval process. The move is intended to ensure consumers would have access to devices at reasonable prices, according to the government. NPPA has recommended the device price be set according to its type, such as cardiac equipment used in government hospitals. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.